Zacks: Brokerages Expect Taysha Gene Therapies, Inc. (NASDAQ:TSHA) to Announce -$0.99 EPS

Equities research analysts predict that Taysha Gene Therapies, Inc. (NASDAQ:TSHAGet Rating) will post earnings of ($0.99) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Taysha Gene Therapies’ earnings, with estimates ranging from ($1.31) to ($0.72). Taysha Gene Therapies posted earnings of ($1.09) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 9.2%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Taysha Gene Therapies will report full year earnings of ($3.96) per share for the current year, with EPS estimates ranging from ($4.73) to ($3.30). For the next financial year, analysts forecast that the company will report earnings of ($3.59) per share, with EPS estimates ranging from ($6.29) to ($2.65). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Taysha Gene Therapies.

Taysha Gene Therapies (NASDAQ:TSHAGet Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.28). During the same period last year, the company posted ($0.87) earnings per share.

A number of research firms have recently commented on TSHA. Truist Financial lowered their target price on Taysha Gene Therapies from $60.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, April 1st. Wells Fargo & Company began coverage on Taysha Gene Therapies in a research report on Tuesday, March 1st. They set an “overweight” rating and a $25.00 target price for the company. JMP Securities lowered their target price on Taysha Gene Therapies from $44.00 to $36.00 and set a “market outperform” rating for the company in a research report on Friday, April 1st. Needham & Company LLC decreased their price target on Taysha Gene Therapies to $20.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Robert W. Baird assumed coverage on Taysha Gene Therapies in a report on Wednesday, March 9th. They set an “outperform” rating and a $26.00 price target on the stock. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $29.64.

Shares of NASDAQ TSHA traded up $0.01 during midday trading on Friday, reaching $3.04. 5,555 shares of the stock traded hands, compared to its average volume of 260,958. The company has a quick ratio of 3.08, a current ratio of 3.08 and a debt-to-equity ratio of 0.39. Taysha Gene Therapies has a one year low of $2.69 and a one year high of $26.99. The company’s 50 day moving average is $5.16 and its 200 day moving average is $8.82.

A number of hedge funds have recently modified their holdings of TSHA. Morgan Stanley boosted its holdings in Taysha Gene Therapies by 57.3% in the second quarter. Morgan Stanley now owns 36,110 shares of the company’s stock worth $766,000 after acquiring an additional 13,149 shares in the last quarter. Royal Bank of Canada boosted its holdings in Taysha Gene Therapies by 75.1% in the second quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $32,000 after acquiring an additional 657 shares in the last quarter. Bank of America Corp DE boosted its holdings in Taysha Gene Therapies by 64.1% in the second quarter. Bank of America Corp DE now owns 24,379 shares of the company’s stock worth $517,000 after acquiring an additional 9,524 shares in the last quarter. Millennium Management LLC boosted its holdings in Taysha Gene Therapies by 42.8% in the second quarter. Millennium Management LLC now owns 30,165 shares of the company’s stock worth $639,000 after acquiring an additional 9,040 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Taysha Gene Therapies in the third quarter worth about $171,000. 46.05% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies (Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Stories

Get a free copy of the Zacks research report on Taysha Gene Therapies (TSHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.